Kepler Capital Sticks to Its Buy Rating for Valneva (0OB3)
TipRanks (Sun, 22-Feb 7:16 AM ET)
TipRanks (Fri, 20-Feb 6:40 AM ET)
Valneva Posts Stable 2025 Revenue, Sets 2026 Outlook Ahead of Key Lyme Vaccine Data
TipRanks (Thu, 19-Feb 6:50 AM ET)
Valneva sees lower 2026 sales as third-party revenue winds down
Seeking Alpha News (Thu, 19-Feb 5:13 AM ET)
Valneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provides 2026 Outlook
Globe Newswire (Thu, 19-Feb 1:00 AM ET)
Valneva Provides Update on Recommendations for Use of IXCHIQ in the United Kingdom
Globe Newswire (Fri, 13-Feb 11:45 AM ET)
Globe Newswire (Tue, 3-Feb 1:00 AM ET)
Valneva Provides Update on Chikungunya Vaccine IXCHIQ
Globe Newswire (Mon, 19-Jan 12:00 PM ET)
Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference
Globe Newswire (Fri, 9-Jan 1:00 AM ET)
Globe Newswire (Wed, 10-Dec 11:45 AM ET)
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Valneva Se - American Depositary Shares trades on the NASDAQ stock market under the symbol VALN.
As of February 24, 2026, VALN stock price climbed to $11.90 with 49,138 million shares trading.
VALN has a beta of 1.52, meaning it tends to be more sensitive to market movements. VALN has a correlation of 0.16 to the broad based SPY ETF.
VALN has a market cap of $1.03 billion. This is considered a Small Cap stock.
Last quarter Valneva Se - American Depositary Shares reported $34 million in Revenue and -$.61 earnings per share. This fell short of revenue expectation by $-16 million and missed earnings estimates by -$.31.
In the last 3 years, VALN traded as high as $17.05 and as low as $3.62.
VALN has outperformed the market in the last year with a price return of +59.9% while the SPY ETF gained +15.7%. VALN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +38.1% and +22.9%, respectively, while the SPY returned +4.5% and -1.0%, respectively.
VALN support price is $10.95 and resistance is $11.93 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VALN shares will trade within this expected range on the day.